Regulatory filing by diagnostic lab citing a New England Journal of Medicine paper — Natera, 2025-11-06
NateraNateraNASDAQ NTRA
Filings SEC · Quote Yahoo cited a paper published in the New England Journal of Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the way the paper was written and the scope it actually demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this
When a U.S. listed company has something to inform shareholders, the unscheduled report submitted to the Securities and Exchange Commission is called 8-K. The item number of the document submitted by Natera on 2025-11-06 was 2.02 Earnings announcement · 9.01 Financial statements · Attached documents. The company cited a paper published in New England Journal of Medicine in the press release attached to it. If you copy the sentence citing the paper verbatim from the original, it reads as follows.
Not for reproduction or further distribution. 10 ESMO Congress: practice - changing evidence in muscle - invasive bladder cancer “This is the strongest evidence to date for intervening with adjuvant systemic therapy on the basis of detecting plasma ctDNA .” Alex Wyatt, D.Phil, University of British Columbia, ESMO Congress (IMvigor011 study discussant), 10/20/25 Checkmate 274: Annals of Oncology 2 IMvigor011: New England Journal of Medicine 1 1.
What readers should look at first is where the company placed the paper in the press release. Next is to determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, you need to read the full paper. This article, which reads only the abstract, cannot answer that.
The scope of the paper mentioned in the abstract is up to here.
The paper title is ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer and it was published in New England Journal of Medicine on 2025-10-20. The authors' affiliations are Queen Mary University of London · Hospital Alemão Oswaldo Cruz · Hospital Universitario 12 De Octubre · Université de Bordeaux. The summary published at the beginning of the paper is called abstract. What this article has read is only up to there. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract by numerical comparison, so it is a different grade from a full-text reading and a verified reading.
A phase 3 trial compared the immune checkpoint inhibitor atezolizumab with a placebo in patients with muscle-invasive bladder cancer who had undergone cystectomy. Tumor DNA fragments were repeatedly detected in the blood of 250 out of 761 enrolled patients over one year, and these patients were randomly assigned in a two-to-one ratio to receive injections every four weeks. The primary endpoint was the duration of progression-free survival. The median progression-free survival was 9.9 months in the atezolizumab group and 4.8 months in the placebo group. Patients who remained negative were not treated, so these results apply only to those who tested positive.
The unanswered questions remain in the full text and appendices. This summary leaves gaps as they are. Readers must compare the two citations above to determine which sentence in the abstract corresponds to the company's referenced excerpt.
One month later, the stock price was within the top quarter of the sample.
The portion of returns not explained by market movement is called excess return. Dates are counted in trading days, the days when the stock market is open. In calendar terms, 20 trading days is roughly one month. The excess returns for the day of the announcement and the following month are presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the announcement | +5.9% | The extent of movement before the filing |
| On the filing date | +1.1% | On the filing date or the first trading day afterward |
| Cumulative over +1 to +5 trading days | +2.9% | One week |
| Cumulative over +1 to +20 trading days | +18.7% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +18.7% in this case is in the top quarter, corresponding to the 89% position from the bottom among 142 samples.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | Median | Top 25% | Top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | +18.7% |
Half of the sample falls between the two central marks on the chart. One checks the chart to see whether this case lies within or outside the range. The sample consists of cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules applicable to future cases.
There are four additional cases where the same company cited papers in 8-K filings, which are included in the table below.
| Filing date | Journal of the cited paper | Excess return over one month |
|---|---|---|
| 2021-11-04 | Clinical Journal of the American Society of Nephrology | −13.1% |
| 2022-11-08 | Transplantation | −12.1% |
| 2023-02-28 | Journal of Genetic Counseling | +18.2% |
| 2024-08-08 | Journal of Clinical Oncology | +3.9% |
Documents issued by the company after the filing
Only item numbers are listed for the three 8-K filings issued by the company after the filing date. In 8-K filings without titles, item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be determined by the item number. The specific event is described in the original text of each link.
- 2025-12-05 8-K Items 3.02,8.01,9.01 — Unregistered securities sale · Other events · Financial statements and exhibits
- 2026-01-12 8-K Item 2.02, 9.01 — Earnings announcement · Financial statements · Attached documents
- 2026-02-26 8-K Item 2.02, 9.01 — Earnings announcement · Financial statements · Attached documents
What this article does not answer
This article, which reads only abstracts, cannot answer what the paper reviewed, how it was tested, or what it showed. How many times the paper cited by the company has been cited afterward can be verified again through the OpenAlexOpenAlex
Data source · Website citation count. What will be seen next is whether the company's next 8-K again cites the same paper.
Explanation of terms
- 8-K
- A voluntary report submitted to the U.S. Securities and Exchange Commission when a listed company has something to inform shareholders. The type is indicated by item numbers such as earnings, contracts, and executive changes. All events in this article come from this document.
- Excess return
- The remainder obtained by subtracting the market's overall return from the stock's return. It is used to observe the company's unique movement after removing the portion attributable to the market's collective rise or fall.
- Trading day
- A date counting only the days the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom within it is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details or limitations of the method.